2023-10-06 10:02:43
Fagron distributes raw materials for pharmaceutical use, offering healthcare professionals the possibility of formulating personalized medicines adapted to each patient.
Adapt dosages and forms of administration
Founded in 1990 in the Netherlands, the company Fagron (for FArmaceutische GRONdstoffen, meaning “pharmaceutical raw materials” in Dutch) has since become a leader in the distribution of MPUP (raw material for pharmaceutical use). These MPUPs allow preparers (pharmacists, hospitals, manufacturers, etc.) to produce personalized pharmaceutical preparations at the request of prescribers in order to meet the specific needs of each patient. It is thus possible to adapt the dosage to deliver a “tailor-made” dose to the patient. Likewise, the forms of administration can vary to adjust to each person’s profile (presence of allergies, swallowing problems, etc.), going from a capsule to a cream for example.
Thanks to its flexible approach and strong partnerships with supply chain players, Fagron responds to a wide range of specific and varied requests. In addition to common medications, the company provides its customers with formulations adapted to the requirements and needs of certain patients (geriatrics, pediatrics, etc.), such as MediSpend, a preparation that helps swallow pills more easily. , tablets or capsules.
Fagron provides all the equipment necessary for the preparations: the molecule and excipients, the bottles, the laboratory equipment, and even pharmacogenetic tests. By analyzing a patient’s genes, they can predict their reaction to a medication, and therefore push the personalization of the preparation even further. Fagron has factories allowing the repackaging of large volumes in small quantities and weights. The company distributes nearly 2,000 raw materials to 300,000 customers in more than 30 countries.
Improve access to care
Epidemics of COVID-19, flu and bronchiolitis, war in Ukraine and rising energy prices have led to numerous supply shortages of certain medications, particularly pediatric versions, in recent years. To address these issues, exceptional measures from the ANSM (National Medicines Safety Agency) have recently enabled authorized pharmacists to produce so-called “magistral” preparations of certain molecules such as amoxicillin.
By working in close consultation with the ANSM, the ARS (Regional Health Agencies), the pharmaceutical industry and of course healthcare professionals, Fagron pursues the objective of a reliable and continuous supply of medicines. To do this, the company relies on reports from the ANSM and independent organizations in order to anticipate market needs. At the same time, through the Fagron Academy, the company provides training on pharmaceutical preparations and personalization of medicine. Finally, she works to improve access to care through the Fagron Foundation.
Content designed and offered by L’Agence Delta. The editorial staff of Le Figaro did not participate in the production of this article.
1696640640
#Fagron #tailormade #medicines
